Nuri ÖZKÜTÜK, Nezaket KALIR, Nuran ESEN, Ayşe Aydan ÖZKÜTÜK

Pyrazinamide monoresistance in clinical isolates

To determine pyrazinamide (PZA) monoresistance in clinical isolates of Mycobacterium tuberculosis complex (MTBC) isolated in hospitals in and around İzmir. Materials and methods: The study was performed between 2004 and 2009 with 150 streptomycin, isoniazid, rifampicin, and ethambutol susceptible MTBC clinical strains isolated in the university hospitals of İzmir and Manisa. The PZA susceptibility of the isolates was determined by the BACTEC 460 TB test. Results: The results indicated that resistance to PZA was present in 5 (3.3%) of the 150 MTBC isolates susceptible to all primary drugs except PZA. Conclusion: It is not essential to perform PZA susceptibility tests routinely along with other primary drugs due to the low PZA monoresistance level in our region.

Anahtar Kelimeler:

Key words: Mycobacterium tuberculosis, antituberculosis susceptibility test, pyrazinamide resistance, BACTEC 460TB

Pyrazinamide monoresistance in clinical isolates

Keywords:

Key words: Mycobacterium tuberculosis, antituberculosis susceptibility test, pyrazinamide resistance, BACTEC 460TB,

PDF

___

Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540–3.
National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; Approved Standard, NCCLS document M24-A, 2003, Pennsylvania, USA. 3. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31: 209–11.
Davies AP, Billington OJ, McHugh TD, Mitchison DA, Gillespie SH. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol 2000; 38: 3686–8.
Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6–21.
Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 1988; 32: 100–4.
World Health Organization. Global Tuberculosis Control, Surveillance, Planning, Financing. Geneva: WHO Report; 2008.
Bilgiç H. Dünyada tüberkülozun durumu. VI. Ulusal Mikobakteri Sempozyumu Kitabı. Kızılcahamam. Türk Mikrobiyoloji Cemiyeti 2006: 17–21.
Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsaker T, Muthivhi T et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008; 10: 3459–64.
Krishnamurthy A, Almeida D, Rodrigues C, Mehta A. Comparison of pyrazinamide drug susceptibility of M. tuberculosıs by radiometric BACTEC and enzymatic pyrazinamidase assay. Indian J Med Microbiol 2004; 22: 166– 85.
Stottmeier KD, Beam RE, Kubica GP. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am Rev Respir Dis 1967; 96: 1072–5.
Della-Latta P. Mycobacteriology and antimycobacterial susceptibility testing. In: Isenberg HD (Editor in Chief), Clinical Microbiology Procedures Handbook. 2nd ed. Washington, DC: ASM Publishers; 2004.
Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 System for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2010; 48: 300–1.
Zhou M, Geng X, Chen J, Wang X, Wang D, Deng J et al. Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. PLoS One 2011; 6: e27654. Epub 2011 Nov 10.
Miller MA, Thibert L, Desjardins F, Siddiqi SH, Dascal A. Growth inhibition of Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC pyrazinamide susceptibility test. J Clin Microbiol 1996; 34: 84–6.
Furtado C, Brum L. Laboratory surveillance of drug resistance tuberculosis in Portugal in 2000–2001. Rev Port Pneumol 2003; 9: 279–91.
Alrajhi AA, Abdulwahab S, Almodovar E. Risk factors for drug-resistant Mycobacterium tuberculosis in Saudi Arabia. Saudi Med J 2002; 23: 305–10.
Javaid A, Rizvi N, Angari M. Primary drug resistance to anti- tuberculous drugs in Karachi. J Coll Physician Surg Pak 2008; 18: 699–702.
Louw GE, Warren RM, Donald PR, Murray MB, Bosman M, Van Helden PD et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006; 10: 802–7.
Cheng S Ji, Thibert L, Sanchez T, Heifets L, Zhang Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 2000; 44: 528–32.
Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N, Elisarova E et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 2005; 60: 130–5.
Yolsal N, Malat G, Dişçi R, Orkun M, Kılıçaslan Z. Türkiye’de tüberküloz ilaçlarına direnç sorununun 1984–1989 ve 1990– 1995 yılları için karşılaştırılması: Meta-analiz. Klimik Derg 1998; 11: 6–9.
Karadağ A, Tokaç M, Güvenli A, Sünbül M, Günaydın M, Saniç A. Klinik örneklerden izole edilen tüberküloz basili kompleksinin majör antitüberküloz ilaçlara direnç oranları. Ankem Derg 2004; 18: 189–92.
Özkütük N, Ecemiş T, Sürücüoğlu S. Pyrazinamide monoresistant Mycobacterium tuberculosis in Manisa region, Turkey. Mikrobiyol Bul 2008; 42: 585–90.
Şenol G, Coşkun M, Gündüz A, Biçmen C, Gayaf M, Özsöz A. Investigation of pyrazinamide resistance in multidrug- resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey. Mikrobiyol Bul 2008; 42: 591–7.
Dankner WM, Waecker NJ, Essey KM, Thompson M, Davis CE. Mycobacterium bovis infection in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine 1993; 72: 11–37.
Nolte FS, Metchock B. Mycobacterium, In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds.), Manual of Clinical Microbiology, 7th ed. Washington, DC: ASM Press; 1999. p. 399–437.
Hannan M, Desmond PE, Morlock GP, Mazurek GH, Crawford JT. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J Clin Microbiol 2001; 12: 647–50.